Ryvis Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 17-11-2024
- Paid Up Capital ₹ 0.10 M
as on 17-11-2024
- Company Age 16 Year, 26 Days
- Last Filing with ROC 31 Mar 2024
- Revenue -9.12%
(FY 2023)
- Profit 42.90%
(FY 2023)
- Ebitda 41.56%
(FY 2023)
- Net Worth -37.94%
(FY 2023)
- Total Assets -2.46%
(FY 2023)
About Ryvis Pharma
The Corporate was formerly known as Vyser Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Gopal Sethi, Seema Sethi, Upasana Bhatia, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232DL2008PTC185273
- Company No.
185273
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Nov 2008
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Ryvis Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gopal Sethi  | Director | 26-Nov-2008 | Current |
| Seema Sethi | Director | 26-Nov-2008 | Current |
Upasana Bhatia  | Director | 30-Dec-2016 | Current |
| Karuna Bhatia | Director | 28-Oct-2019 | Current |
Financial Performance of Ryvis Pharma.
Ryvis Pharma Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 9.12% decrease. The company also saw a substantial improvement in profitability, with a 42.9% increase in profit. The company's net worth observed a substantial decline by a decrease of 37.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ryvis Pharma?
In 2023, Ryvis Pharma had a promoter holding of 99.98% and a public holding of 0.02%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ryvis Pharma?
Unlock and access historical data on people associated with Ryvis Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ryvis Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ryvis Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
